196
Participants
Start Date
November 6, 2019
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2027
AB680
AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
Zimberelimab
Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
Nab-paclitaxel
Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
Gemcitabine
Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
NYU Cancer Institute, New York
Columbia University, New York
Memorial Sloan Kettering Cancer Center, New York
UPMC Hillman Cancer Center, Pittsburgh
University of Pennsylvania, Philadelphia
Thomas Jefferson University Hospital, Philadelphia
BRCR Global, Plantation
Sarah Canon Research Institute, Nashville
UW Health - UW Carbone Cancer Center - Medical Oncology Clinic, Madison
Washington University School of Medicine - Siteman Cancer Center, St Louis
Stephenson Cancer Center, Oklahoma City
The University of Texas MD Anderson Cancer Center, Houston
START San Antonio, San Antonio
The Angeles Clinic, Los Angeles
UCLA Hematology Oncology, Santa Monica
Yale Cancer Center, New Haven
Lead Sponsor
Arcus Biosciences, Inc.
INDUSTRY